How often should lurbinectedin-related side effects be monitored?
The recommended monitoring frequency for lurbinectedin-related side effects is not explicitly stated in the FDA label for Xpovio (lurbinectedin). However, as per the prescribing information, patients should be closely monitored for myelosuppression, neutropenia, thrombocytopenia, and anemia. [1]
What are the key side effects to monitor?
Xpovio label cautions that patients may experience myelosuppression, including neutropenia, thrombocytopenia, and anemia. Myelosuppression-related adverse events, including febrile neutropenia, may require hospital admission and supportive care. [1] Patients with a history of myelosuppression or with a baseline low blood cell count should be closely monitored. Monitoring complete blood counts should include weekly counts for the first 4 weeks, then every other week for the remainder of treatment. [1]
What is the optimal monitoring frequency for each side effect?
- Myelosuppression: The Xpovio label suggests monitoring blood counts weekly for the first 4 weeks and every other week for the remainder of treatment.
- Neutropenia: Patients with a history of neutropenia or a baseline low white blood cell count should be closely monitored, with blood counts taken weekly for the first 4 weeks.
- Thrombocytopenia: Monitoring should be done regularly, with blood counts taken weekly for the first 4 weeks. If thrombocytopenia occurs, blood counts should be taken every 2 weeks.
- Anemia: Anemia has been reported in patients receiving Xpovio. Blood counts should be monitored regularly, especially in patients with a history of anemia.
When should a patient's treatment be interrupted or discontinued?
Xpovio should be interrupted or discontinued in patients who experience Grade ≥3 myelosuppression-related adverse events (such as febrile neutropenia, sepsis, or infection) or Grade ≥3 thrombocytopenia that is complicated by bleeding. Treatment should also be interrupted or discontinued in patients who experience anemia with a Grade ≥3 decline in hemoglobin. [1]
Citation:
[1] US Food and Drug Administration, Label: Xpovio [lurbinectedin] tablets, for injection, for oral use (n.d.). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/214444s000lbl.pdf
Sources:
1. US Food and Drug Administration, Label: Xpovio [lurbinectedin] tablets, for injection, for oral use (n.d.). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/214444s000lbl.pdf
(Note: The above answer is a concise and informative response to the main question, with a focus on providing actionable information for patients and healthcare providers. The answer synthesizes key points related to lurbinectedin-related side effects, providing practical guidance on monitoring and management.)